TL1A Inhibitors in IBD‐Mechanistic Rationale and Clinical Evidence
1. 系统已在2026-04-27 16:36:47对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
MK Goyal, H Srivastava, T Sehgal…
Alimentary …, 2026
Wiley Online Library
Background Tumour necrosis factor‐like ligand 1A (TL1A) and its receptor DR3 form a pivotal signalling dyad linking immune activation, epithelial barrier dysfunction and fibrogenesis in inflammatory bowel diseases.(IBD). Aims This narrative review summarizes the molecular biology of the TL1A–DR3 axis, its roles in intestinal inflammation, fibrosis, and extraintestinal manifestations, and the emerging therapeutic landscape of TL1A inhibition in IBD. Methods Narrative synthesis of preclinical, translational, and clinical literature on …
